TEG 6s

"In summary, modified VET assays show promise as rapid point-of-care tools for DOAC detection in emergency settings. Ecarin-based tests appear reliable for dabigatran, while Russell's Viper Venom and low-tissue-factor approaches may enable detection of direct factor Xa inhibitors. However, further clinical validation and standardization are required before routine implementation."

"This is the first study to systematically compare multiple next generation VET and platelet aggregation systems in both healthy and septic patients under controlled PTS transport conditions. It is hypothesized that PTS-induced acceleration may alter test results. Identifying a critical threshold could ensure safe, rapid blood transport without compromising diagnostic quality, potentially reducing personnel needs and expediting therapy initiation."

"A new algorithm for cardiac surgery based on TEG 6s assays has been proposed based on the available evidence and expert opinion for research alignment and clinical validation."

"The standalone performance of early VHA testing in the ED setting was insufficient to reliably for predict a need for massive transfusion."

This study demonstrates that the 10-minute amplitude (A10) in TEG6s measurements is a reliable predictor of maximum amplitude (MA). By establishing a strong correlation between these values, clinicians can infer final results much earlier, enabling faster preparation and administration of blood products to improve coagulation management in critical care settings.

"The case for routine testing of antiplatelet therapy in interventional cardiology patients is strong but could only be translated into clinical practice if a simple, quick, easy to use, accurate, reproducible assay was available. TEG6S is a candidate for such a role. To move this concept forward, a careful observational study of a large number of PCI patients would be needed in order to set well validated ranges for normal, high and low responses to aspirin and clopidogrel. Following this, these normal ranges could be applied to patients on aspirin and clopidogrel in order to identify hypo- and hyper-responders. For the former, increased doses of aspirin, or a switch from clopidogrel to prasugrel or ticagrelor, could be tailored to their response."

Recent research highlights fibrinogen as a critical determinant of arterial thrombosis, particularly in patients with cardiovascular disease and COVID-19. The study demonstrates that higher fibrinogen levels significantly increase platelet-fibrin clot strength (P-FCS), a known risk factor for ischemic events following coronary interventions. Notably, this influence remains potent even in the presence of strong antiplatelet therapy, suggesting that fibrinogen may be as significant a risk factor as high platelet reactivity itself. These findings underscore the necessity of further investigating fibrinogen's role to better personalize antithrombotic treatments and improve clinical outcomes for high-risk patients.

"TEG analysis showed that treatments of TB and TBI were associated with reduced MA which may indicate the existence of cardiovascular benefits from therapy."

While new cartridge-based VHA devices simplify point-of-care testing, their clinical value is not yet fully established. Current research highlights a lack of interchangeability between devices and a shortage of data linking them to patient outcomes or comparing them to rapid conventional assays. Consequently, despite their technical promise, robust randomized clinical trials are still required to prove their utility in critical care settings.

Viscoelastic testing (VET) has revolutionized modern coagulation management by offering rapid, real-time insights into the entire hemostatic process. By enabling precise, data-driven transfusion algorithms at the point of care, VET-guided strategies significantly improve patient blood management and clinical outcomes in high-stakes environments like trauma and cardiac surgery.

"Compared with the preoperative period, coagulation tended to increase, and platelet contribution to clot strength decreased from days 1 to 3 after TAVI."

"Both TEG 5000-FLEV and TEG 6s-CFF correlated moderately with Clauss fibrinogen but decreased in correlation in both hyperfibrinogenemia and hypofibrinogenemia. Thus, we caution relying on TEG 5000 or TEG 6s to be the only laboratory measurement to guide fibrinogen replacement when resuscitating trauma patients at risk for TIC and TEG 5000-FLEV for assessing fibrinogen in patients with ESRD at risk for thrombotic events."

"Upregulated thrombin generation parameters after PCC spiking were not displayed by CT, ACT [ROTEM® Delta, ClotPro®, TEG®6s, and Quantra®], or standard tests. Our results do not support treatment algorithms using prolonged CT or ACT as a trigger for administration of PCC to augment thrombin generation."

"The TEG6s CFF assay demonstrates a strong correlation with Clauss fibrinogen levels before CPB, but this relationship weakens during CPB and remains moderate post-protamine administration. Despite limitations during high-heparin states, the TEG6s offers significantly faster results, suggesting utility for real-time intraoperative decision-making. However, CFF values alone are insufficient to predict postoperative bleeding. Further large-scale studies are needed to validate the integration of TEG6s into transfusion algorithms in cardiac surgery."

VHA-guided MHP showed marked variation with inconsistent transfusion thresholds [ROTEM® Sigma and TEG 6 s platforms within major haemorrhage protocols]. For similar clot kinetics, dosing of blood products and haemostatic agents differed, particularly PCC. Patients with the same coagulopathy may receive different treatment across hospitals. Centralised standardisation could improve PBM consistency.

"Using citrated-recalcified blood to perform TEG might lead to underestimation of the effect of heparin."

"The present study revealed acceptable agreement between four different assays measuring functional fibrinogen, with current- and previous-generation ROTEM® machines (Sigma, Delta) performing similarly measuring functional fibrinogen via FIBTEM assay. This suggests that haemostatic resuscitation algorithms designed for the ROTEM® Delta can be applied to the ROTEM® Sigma to guide fibrinogen replacement."

All three point-of-care devices (ROTEM Delta, TEG 6s, and Quantra) show a high correlation with laboratory Clauss fibrinogen, making them equally effective for the early detection of hypofibrinogenemia in pregnant patients. However, the cartridge-based Quantra and TEG 6s systems eliminate manual pipetting, with the Quantra being approximately 21 minutes faster than the ROTEM when accounting for reagent preparation. Ultimately, while all devices are reliable for managing obstetric hemorrhage, the automated systems offer a significant advantage in speed and ease of use during clinical emergencies.

This prospective study demonstrates that the TEG5000 and TEG6s systems show substantial diagnostic agreement when assessing hemostasis in pediatric cardiac surgery patients. While some variability was noted in reaction times, the devices displayed low bias and high consistency in measuring critical parameters like Maximum Amplitude (MAK) and K time (KK). These findings suggest that the two platforms are clinically interchangeable for monitoring clot strength and formation in this vulnerable population.

"CK LY30 above the ULN is a sensitive but not specific cutoff for hyperfibrinolysis. At least moderately elevated CK LY30 carries more clinical portent on the TEG 6s instrument than on the TEG 5000. These TEG instruments are not sensitive to low concentrations of tPA."

Traditional coagulation tests (PT/APTT) often fail in the NICU because they do not account for developmental hemostasis—the unique, balanced clotting state of newborns. This often leads to unnecessary and potentially harmful blood transfusions. In contrast, Viscoelastic Coagulation Tests (VCTs) like TEG and ROTEM offer a rapid, bedside "global" view of clotting using minimal blood volumes. By providing real-time data, VCTs enable individualized, goal-directed therapy for critical conditions such as sepsis and ECMO, effectively optimizing blood product use and improving neonatal outcomes.

Modern cartridge-based VET - specifically the TEG 6s, HemoSonics Quantra, and ROTEM sigma - offers superior portability and ease of use compared to traditional laboratory methods. Despite limited randomized evidence for these new-generation devices, VET-guided algorithms effectively reduce blood product usage without compromising patient outcomes. Future validation of clinical cut-offs will be key to optimizing transfusion management.

"TEG could help physicians to determine need for idarucizumab and also an adequate dose of heparin to establish appropriate anticoagulation for CPB."

"In vitro protamine addition allows assessment of coagulation status during CPB using the TEG 6s system. CK-MA and CFF-MA measured during CPB using this method revealed a strong correlation and agreement with post-CPB measurements, suggesting that our method potentially facilitates early prediction of post-CPB coagulation status and decision-making on transfusion strategies."

The study demonstrates that the TEG 6s global hemostasis system serves as a superior tool for perioperative coagulation management during liver transplantation compared to standard laboratory tests. By providing rapid, point-of-care insights into the complex balance of pro- and anticoagulation factors, the system allows anesthesiologists and surgical teams to make precise, data-driven decisions regarding transfusion and the management of bleeding complications. Ultimately, the comprehensive monitoring capabilities of the TEG 6s facilitate more effective clinical responses to the high-risk hemodynamic challenges inherent in end-stage liver disease surgery.

"This study established NRRs for the Global Hemostasis cartridge and serves as a proof of concept for the validity of results obtained using this cartridge."

"In the present patient who underwent cardiopulmonary bypass, TEG6s may have contributed to a reliable and useful assessment of coagulation and hemostatic status avoiding unnecessary platelet transfusions."

Fibrinogen substitution in infants was associated with younger age and higher RACHS‐1 category. The prognostic value of TEG6s was evaluated, and cryoprecipitate transfusion was related to TEG‐FF‐MA values, but also CPB‐time, surgical complexity, and in particular excessive intraoperative bleeding. A clear‐cut threshold for TEG‐FF‐MA is difficult to establish in infants undertaken congenital heart surgery.

"The TEG6s represents an easy-to-use VHA that enables multiple simultaneous measurements using only minimal amounts of blood and provides a user-friendly experience. Initiating viscoelastic coagulation measurement on the TEG6s during air medical transport in a helicopter does not seem feasible due to the high-vibration artifacts. However, starting a measurement 10 min before turning on helicopter engines or take-off might be considered an interesting option for future studies and clinical decision-making with this device in critical situations where starting coagulation management during flight operation is considered."

"We report reagent-analyzer specific pediatric RIs for TEG 6s and coagulation parameters. Observed variation reinforces recommendations for laboratory-specific RIs. These findings improve accuracy of interpretation of clinical results, provide a foundation for comparison and validation of tests in pathology, and illustrate feasibility and advantages of model-based RI approaches."